Reference: Informed Consent Action Network. (2022). V-safe data. https://icandecide.org/v-safe-data/#v-safe-downloads Summary: The V-Safe Data report from the Informed Consent Action Network (ICAN) presents comprehensive statistics on adverse health impacts following COVID-19 vaccinations. The data indicates that over 10 million individuals registered on the V-Safe platform, with significant health impacts reported, totalling approximately 6.4 million. The report […]
Reference: General patient consent form for pharmacies during 2021. Summary: General consent form drawn up for pharmacies dispensing Ivermecting to patients during 2021. DOWNLOAD
Reference: Kory, P., Meduri, G. U., Varon, J., Iglesias, J., & Marik, P. E. (2021). Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. American Journal of Therapeutics, 28(3), e299–e318. https://doi.org/10.1097/MJT.0000000000001163 Summary: This article reviews evidence supporting ivermectin as an effective treatment and prophylactic agent for COVID-19.
Reference: Law, B. (2020). Priority List of COVID-19 Adverse events of special interest: Quarterly update December 2020. Safety Platform for Emergency Vaccines. Summary: The report updates the list of adverse events of special interest AESI) associated with COVID-19 vaccines, generated by the Safety Platform for Emergency Vaccines (SPEAC) Project. The quarterly review focuses on new
Reference: McGee, S., & De Waal, R. (2020). Rapid review of remdesivir for COVID-19: Update 15 December 2020. South African National Department of Health. Summary: The South African National Department of Health conducted a rapid review of remdesivir’s efficacy for treating hospitalised COVID-19 patients. The analysis included five randomised controlled trials (RCTs) with over 7,700
Reference: U.S. Food and Drug Administration. (2020). Vaccines and related biological products advisory committee meeting December 10, 2020 FDA briefing document Pfizer-BioNTech COVID-19 vaccine. https://www.fda.gov/media/144246/download Summary: On December 10, 2020, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) reviewed Pfizer-BioNTech’s COVID-19 vaccine, BNT162b2, which received an Emergency Use Authorization (EUA) request on November 20,
Reference: Joi, P. (2020). What is the difference between efficacy and effectiveness? Gavi, the Vaccine Alliance. Retrieved from https://www.gavi.org/vaccineswork/what-difference-between-efficacy-and-effectiveness Summary: Efficacy and effectiveness are two crucial terms in vaccine science, often conflated but distinct. Efficacy refers to the performance of a vaccine under ideal, controlled conditions, typically demonstrated in clinical trials where a vaccinated group
Reference: Anderson, S. (2020). CBER plans for monitoring COVID-19 vaccine safety and effectiveness. Vaccines and Related Biological Products Advisory Committee Meeting, FDA. Summary: The FDA’s Centre for Biologics Evaluation and Research (CBER) presented its comprehensive strategy for monitoring the safety and effectiveness of COVID-19 vaccines during the VRBPAC meeting on October 22, 2020. The approach
Reference: Tang, M., Hu, X., Wang, Y., Yao, X., Zhang, W., Yu, C., Cheng, F., Li, J., & Fang, Q. (2021). Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research, 163, 105207. https://doi.org/10.1016/j.phrs.2020.105207 Summary: Since January 2020, Elsevier has provided a COVID-19 resource centre offering free access to research on the virus,
Reference: National Institutes of Health. (2020, July 27). Phase 3 clinical trial of investigational vaccine for COVID-19 begins. https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins Summary: The National Institutes of Health (NIH) has commenced a Phase 3 clinical trial to assess the efficacy of the investigational mRNA-1273 vaccine, co-developed by Moderna, Inc. and NIH’s National Institute of Allergy and Infectious Diseases